Rash, anemia among adverse events seen in HCV patients taking DAA – Healio


Rash, anemia among adverse events seen in HCV patients taking DAA
Healio
Adverse events reported included anemia, which developed in 85% of patients, and rash in 24%. In patients treated with telaprevir, 23% developed rash, while 0% of patients treated with boceprevir developed rash. Fifty-one percent of patients reported ...

Comments are closed.